Stonebridge Financial Group (Pennsylvania)’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-297
Closed -$20.6K 692
2025
Q1
$20.6K Buy
297
+245
+471% +$20.2K ﹤0.01% 493
2024
Q4
$4.47K Buy
+52
New +$5.62K ﹤0.01% 698

Other funds holding NVO

Stonebridge Financial Group (Pennsylvania)'s NVO Position: Q2 2025 in Review

Stonebridge Financial Group (Pennsylvania) sold out of Novo Nordisk (NVO) in Q2 2025, closing a stake of 297 shares — an estimated $20.6K sold.

Stonebridge Financial Group (Pennsylvania) first reported a position in NVO in Q4 2024 and held it in 2 quarters. The position peaked at $20.6K in Q1 2025. 1,481 funds tracked by Wall St. Rank hold NVO as of Q2 2025.

  • Stonebridge Financial Group (Pennsylvania) reported no remaining Novo Nordisk position as of Q2 2025 after selling out during the quarter.
  • Stonebridge Financial Group (Pennsylvania) sold 297 Novo Nordisk shares in Q2 2025, an estimated $20.6K.
  • Stonebridge Financial Group (Pennsylvania) first reported a position in Novo Nordisk in Q4 2024 and held it in 2 quarters.
  • Stonebridge Financial Group (Pennsylvania)'s Novo Nordisk position peaked at $20.6K in Q1 2025.
  • 1,481 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2025.

Based on Stonebridge Financial Group (Pennsylvania)'s 13F filing for Q2 2025, filed 24 Jul 2025.